



# PHE Weekly National Influenza Report

Summary of UK surveillance of influenza and other seasonal respiratory illnesses

14 August 2014 – Week 33 report (up to week 32 data)



This report is published [online](#). A summary report is being published once a fortnight while influenza activity is low. For further information on the surveillance schemes mentioned in this report, please see information available [online](#).

Indicators of influenza show very low levels of activity.

## Community surveillance

- GP consultation rates for influenza-like illness remain low in all schemes in the UK (Figures 1 and 2).

Scheme	GP ILI consultation rate per 100,000			Peak age group
	Week 32	Week 31		
RCGP (England and Wales)	0.5	0.3	↔	65-74yrs
Scotland	2.5	2.2	↔	15-44yrs
Northern Ireland	5.5	4.4	↔	1-4yrs
Wales	2.2	1.3	↔	75+yrs




- The overall weekly consultation rate for acute bronchitis in England and Wales through the RCGP scheme remained stable at 27.8 per 100,000 in week 32 2014. 75+ year olds had the highest rate followed by 65-74 year olds.

- Syndromic surveillance
  - Syndromic surveillance indicators for influenza remained low in week 32 2014.
  - For further information, please see the Syndromic surveillance [webpage](#).

## Virological surveillance

- English Respiratory Data Mart system
  - In week 32 2014, three (0.8%) of the 354 respiratory specimens tested were positive for influenza (three A(H3), Figure 3).
  - Rhinovirus positivity decreased slightly to 12.7% and adenovirus positivity decreased to 3.3%. Positivity remained low for parainfluenza (2.9%), human metapneumovirus (hMPV) (0.3%) and RSV (1.1%).
- UK GP-based sentinel schemes
  - Through the GP-based sentinel schemes across the UK, no samples were positive for influenza in week 32 2014.




## Outbreak Reporting

- During weeks 31 and 32 2014, no new acute respiratory outbreaks were reported.
- Outbreaks should be reported to the local Health Protection Unit and [Respscidsc@phe.gov.uk](mailto:Respscidsc@phe.gov.uk).

## All-cause mortality surveillance

- In week 31 2014, an estimated 8,916 all-cause deaths were registered in England and Wales (source: Office for National Statistics). This is similar to the 8,965 estimated death registrations in week 30 and remains below the 95% upper limit of expected death registrations for this time of year as calculated by PHE (Figure 4). The sharp drops in number of deaths correspond to weeks when there were bank holidays, and fewer days when deaths were registered, and so are likely to be artificial and result in subsequent increases in following weeks.
- In week 32 2014, no significant excess was reported overall, by age group or by region in England after correcting ONS disaggregate data for reporting delay with the standardised weekly EuroMOMO algorithm (Table 1). This data is provisional due to the time delay in registration and so numbers may vary from week to week.



**Table 1: Excess mortality by age group, England\***

Age group (years)	Excess detected in week 32 2014	Weeks with excess in summer 2014
<5	x	NA
5-14	x	NA
15-64	x	wk 26
65+	x	NA

\* Excess mortality is calculated through the EuroMOMO algorithm as the observed minus the expected number of deaths that week for those weeks where the observed exceeds the upper threshold

## International Surveillance

- Influenza
  - Globally influenza activity continues to increase in the southern hemisphere.
  - In North America and Europe, overall influenza activity remains at inter-seasonal levels.
  - In eastern Asia, influenza activity reached inter-seasonal levels in most countries with influenza A(H3N2) and influenza B virus predominating. Influenza activity still continued in the south region of China mainly due to influenza A(H3N2) viruses.
  - In Africa and western Asia, influenza activity was low.
  - In the southern hemisphere, influenza activity continued to increase in most countries. In the temperate zone of South America influenza-like illness continued to increase, but was predominantly due to respiratory syncytial virus (RSV). Influenza A(H3N2) was the most commonly detected influenza virus. In Australia and New Zealand, the influenza season seemed to have started with increased influenza-like illness and increasing number of influenza detections reported. Influenza A(H1N1)pdm09 the most commonly detected virus. In South Africa the influenza detection rate increased with influenza A(H3N2) the most frequently detected virus.
  - During weeks 29 to 30, National Influenza Centres (NICs) and other national influenza laboratories from 51 countries, areas or territories reported data. The WHO GISRS laboratories tested more than 16203 specimens. 1579 were positive for influenza viruses, of which 1274(80.6%) were typed as influenza A and 305(19.3%) as influenza B. Of the sub-typed influenza A viruses, 426(42.9%) were influenza A(H1N1)pdm09 and 568 (57.1%) were influenza A(H3N2). Of the characterized B viruses, 21 (56.8%) belong to the B-Yamagata lineage and 16 (43.2%) to the B-Victoria lineage
  - For further information, please see the [WHO website](#).
- MERS-CoV
  - Up to 13 August 2014, a total of four cases of Middle East respiratory syndrome coronavirus, MERS-CoV, (two imported and two linked cases) have been confirmed in England. On-going surveillance has identified 199 suspect cases in the UK that have been investigated for MERS-CoV and tested negative. A further 833 confirmed cases have been reported internationally, resulting in a current global total of [837 cases](#), including at least 291 related deaths, which have been officially reported to WHO.
  - Further information on management and guidance of possible cases is available [online](#).
- Influenza A(H7N9)
  - The most recent human infection with influenza A(H7N9) reported by WHO was on [27 June 2014](#). The source of infection is still under investigation. So far, there is no evidence of sustained human-to-human transmission. WHO does not advise special screening at points of entry with regard to this event, nor does it currently recommend any travel or trade restrictions.
  - For further updates please see the WHO website and for advice on clinical management please see information available [online](#).